Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity

Synapse

Volumn 37, Issue 3, 2000, Pages 171-178

  Van Kampen, J M ^a   McGeer, E G ^a   Jon Stoessl, A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

6 Hydroxydopamine; Amphetamine; Levodopa; MPP+; Neurotoxicity

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOPAMINE TRANSPORTER; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PHOSPHODIESTERASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; DISEASE MARKER; DOPAMINE UPTAKE; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; AMPHETAMINE; ANIMALS; APOMORPHINE; AUTORADIOGRAPHY; CARRIER PROTEINS; COCAINE; CORPUS STRIATUM; CYTOPROTECTION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; LEVODOPA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICROINJECTIONS; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SUBSTANTIA NIGRA; TRITIUM;

EID: 0034284635     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2396(20000901)37:3<171::AID-SYN1>3.0.CO;2-R     Document Type: Article

References (32)

1. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M. 1999. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 155:268-273.
2. Buck KJ, Amara SG. 1994. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA 91:12584-12588.
3. Gainetdinov RR, Fumagalli F, Jones SR, Caron M. 1997. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69:1322-1325.
4. Giros B, Caron MG. 1993. Molecular characterization of the dopamine transporter. Trends Neurosci 14:43-49.
5. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
6. Hitri A, Hurd YL, Wyatt RJ, Deutsch SI. 1994. Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin Neuropharmacol 17: 1-22.
7. Itzhak Y, Martin JL, Ali SF, Norenberg MD. 1997. Depletion of striatal dopamine transporter does not affect psychostimulant-induced locomotor activity. Neuroreport 8:3245-3249.
8. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. 1998. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979-1986.
9. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. 1992. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 89:7782-7785.
10. + toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters. Biochim Biophys Acta 1404: 305-313.
11. Kuhar M. 1998. Recent biochemical studies of the dopamine transporter - a CNS drug target. Life Sci 62:1573-1575.
12. Le Couteur DG, Leighton PW, McCann SJ, Pond S. 1997. Association of a polymorphism in the dopamine transporter gene with Parkinson's disease. Move Dis 12:760-763.
13. + uptake and cocaine binding in bovine dopamine transporter. Neurosci Lett 214:199-201.
14. Liang NY, Rutledge CO. 1982. Evidence for carrier-mediated efflux of dopamine from corpus striatum. Biochem Pharmacol 31:2479-2484.
15. + toxicity encodes a vesicular amine transporter. Cell 70:539-551.
16. + toxicity. Mol Brain Res 25:90-96.
17. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI. 1997. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 41:530-539.
18. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates, 2nd ed. New York: Academic Press.
19. Pifl C, Giros B, Caron M. 1993. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13:4246-4253.
20. Pilowsky PM, Suzuki S, Minson JB. 1994. Antisense oligonucleotides: a new tool in neuroscience. Clin Exp Pharmacol Physiol 21:935-944.
21. Reinhard JF Jr, Diliberto EJ Jr, Viveros OH, Daniels AJ. 1987. Subcellular compartmentalization of 1-methyl-4-phenyl-pyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 84:8160-8164.
22. Rudnick G, Wall SC. 1991. Binding of the cocaine analog 2B-[3H] caromethoxy-3B-(4-fluorophenyl)tropane to the serotonin transoporter. Mol Pharmacol 40:421-426.
23. Sanghera MK, Manaye K, McMahon A, Sonsalla PK, German DC. 1997. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. NeuroReport 8:3327-3331.
24. Sano A, Kondoh K, Kakimoto Y, Kondo I. 1993. A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 91:405-406.
25. Seiden LS, Sabol KE, Ricaurte GA. 1993. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639-677.
26. Silvia CP, Jaber M, King GR, Ellinwood EH, Caron MG. 1997. Cocaine and amphetamine elicit differential effects in rats with a unilateral injection of dopamine transporter antisense oligodeoxynucleotides. Neurosci 76:737-747.
27. Simantov R, Blinder E, Ratovitski T, Tauber M, Gabbay M, Porat S. 1996. Dopamine-induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter. Neuroscience 74:39-50.
28. Uhl GR. 1990. Parkinson's disease: neurotransmitter and neurotoxin receptors and their genes. Eur Neurol 30:21-30.
29. Uhl GR. 1998. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43:555-560.
30. Uhl GR, Kitayama S. 1993. A cloned dopamine transporter: potential insights into Parkinson's disease pathogenesis. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, editors. Advances in neurology, 60. Parkinson's disease: from basic research to treatment. New York: Raven Press. p 321-324.
31. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. 1994. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 35:494-498.
32. Wang JB, Moriwaki A, Uhl GR. 1995. Dopamine transporter cysteine mutants: second extracellular loop cysteines are required for transporter expression. J Neurochem 64:1416-1419.